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A commentary on
Structure and function of Parkin E3 ubiq-
uitin ligase reveals aspects of RING and
HECT ligases
by Riley BE, Lougheed JC, Callaway K,
Velasquez M, Brecht E, Nguyen L, et al.
Nat Commun (2013) 4:1982. doi:10.1038/
ncomms2982
Parkinson’s disease (PD) is the second
most common neurodegenerative disor-
der following Alzheimer’s disease. Muta-
tions in several genes are reported to cause
Parkinson’s disease (SNCA,LRRK2,VPS35,
Parkin, PINK1, DJ-1) (1). Parkin muta-
tions are responsible for 50% of auto-
somal recessive juvenile PD and 15% of
young onset (<age of 45) sporadic PD
(1). Parkin has a neuroprotective role
(2) by eliminating damaged mitochon-
dria and reactive oxygen species through
autophagy (mitophagy). Parkin mutations
cause deregulation of the mitochondrial
homeostasis mechanism and subsequent
accumulation of the impaired mitochon-
dria and have a role in cell surface signaling
and tumor suppression (3, 4).
Neuroprotective therapy development
in PD has been frustratingly slow, par-
tially due to the lack of knowledge of the
precise structure of potential target mol-
ecules, such as alpha-synuclein, LRRK2,
or Parkin. Structure-based drug design is
reliant upon identifying the crystal struc-
ture of the target molecule. For exam-
ple, enhancing Parkin housekeeping ability
could stop accumulation of the reactive
oxygen species and subsequent neurode-
generation.
Johnston’s group recently published in
Nature Communications the first crystal
structure of Parkin and described the mol-
ecule at the atomic level (5). Parkin is
a canonical RING-between-RING (RBR)
E3 ligase (Figure 1). E3 ligases have a
crucial role in the final step of ubiqui-
tination by transferring ubiquitin from
E2 enzyme to lysine substrate (6). Stud-
ies suggest that RBR ligases may con-
tain a catalytic cysteine residue, similarly
to HECT ligases (E3 enzymes influencing
specificity of ubiquitylation). The organi-
zation of domains, exact residues, and reg-
ulation of ligase activity remains elusive.
Parkin is activated through phosphoryla-
tion of ubiquitin by PINK1 (do not forget
that mutations in PINK1 are also associ-
ated with autosomal recessive PD). Parkin
is a folded-in-half molecule consisting of
ubiquitin-like domain (UBL), followed by
four RING domains, each bonded to two
Zn atoms (3) (Figure 1). RING 0 (also
called a unique Parkin domain-UPD) (4)
at the N-terminal end is an innovative
structure resembling zinc-finger domain.
RING1-IBR (in between ring) domains are
spatially opposite RING2. Parkin has a
unique RING0:RING2 (C-terminal) bond
which may alter Parkin’s active control site
demonstrated by mass spectrometry to be
at catalytic cysteine 431 (C431) (Figure 1).
Simultaneously, Trempe et al. (2)
confirmed these findings and similarly
described how RING0 occludes the active
site (C431) in RING2, while a flexible IBR-
R2 linker (tether) residue (repressor ele-
ment of Parkin-REP or W403) sits in a
pocket on RING1 and may anchor the
tether to RING1 and block the E2-binding
site (Figure 1). The interface has two com-
pact domains separated by two linkers:
(1) RING1–IBR containing E2-binding site
and (2) RING0–RING2 with the C431
active site (5).
The discovery of the crystal structure
of Parkin provides new opportunities for
defining (1) the molecular function of
Parkin’s target site, (2) the binding of pos-
sible therapeutic particles, (3) the mech-
anism of action of Parkin, and (4) the
modulation/enhancement of novel drug
molecules (7). For example, mutations of
the C431 active site cause loss of the
Parkin mitochondrial degradation mech-
anism (5), whereas deletion of RING0
(lack of occlusion of C431 as described)
causes increased C431 reactivity and Parkin
autoubiquitination (3). Deletion of UBL
domain with/without the linker has lit-
tle effect on Parkin activity (2). Mutations
in hydrophobic residues of RING0:RING2
interface increase autoubiquitination (5).
Crystal structure research and dis-
covery has increased our understand-
ing about lysozyme function, vitamin
B12 action, penicillin, and its modifi-
cations (7, 8) and has been used in
the discovery of the new treatments for
glaucoma (dorzolamide), HIV (protease
inhibitors: saquinavir, indinavir, riton-
avir, and nelfinavir) (9), and chronic
myelogenous leukemia (tyrosinase-kinase
inhibitor- Imatinib) (10). It has also clar-
ified the mechanism of leukemic drug-
resistance (11) and is currently relevant to
HIV1 research with the development of
reverse transcriptase capable of the rapid
crystallization, which will help the design
of new anti-AIDS medications (12).
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FIGURE 1 | Schematic linear structure of Parkin, showing UBL
(ubiquitin-like domain) followed by four RING domains: RING0, RING1,
IBR (in between ring), RING2 with two linkers (IBR-RING2 linker referred
to as tether) indicating an area of potential structural flexibility,
E2-binding site, REP (repressor element), C431 active site residue and
protein residues (1–465), RBR: Ring-between-Ring structure.
In summary, Johnston group have
improved our understanding of the Parkin
structure at the atomic level with the dis-
covery of its crystal structure. Mapping
of Parkin mutations affecting the stabil-
ity of the molecule (mutations in Zn),
catalytic reactions (active site at C431),
and the interactions among domains (E2-
binding site) (3, 4) may help future drug
development in PD and neurodegenera-
tion by enhancing activity at the active site
or by understanding further its molecular
interactions.
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